Press Releases.

- Study Designed to Demonstrate Human Proof-of-Concept Results by YE 2014 -

- Achieved All Goals on 'Road to the Clinic'; Launched 'Clinical Map Initiative'-

-RG-012 is an anti-miR Targeting microRNA-21 for the Treatment of Alport Syndrome, a Life-Threatening, Genetic Kidney Disease with No Approved Therapy-

-Martin Beaulieu, Ph.D. Brings Extensive Diagnostic Assay Development Experience-

-Regulus to Develop microRNA-21 for Alport Syndrome, a Life-Threatening Orphan Kidney Disease, and microRNA-21 in Oncology, to Human Proof-of-Concept-

-Mr. Szekeres Brings Extensive Strategic and Transactional Deal Experience-

-Regulus microMarkers™ Designed to Support Regulus' Therapeutic Pipeline, its Collaborators and Strategic Partners-

- Regulatory Application for RG-101 to be Filed in the Near Term: Clinical Studies in Man Expected to Commence in Early 2014 -

- New Survival Data Presented at Kidney Week 2013 -

- Late-Breaking Poster to be Presented at AASLD -

-'Road to the Clinic' Strategy On Track; Preparing for Clinical Development of RG-101 for HCV; Second microRNA Clinical Candidate to be Nominated by Year End -

Include multimedia assets in your release for better visibility